Trial reportBMC complementary and alternative medicine2018
Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with metabolic syndrome: a randomized clinical trial (PROSIR).
Trial report in BMC complementary and alternative medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02972567 (Evaluation of the Effect of a Lactobacillus Reuteri Strain on Markers of Inflammation, Cardiovascular Risk and Fatty Liver Disease in Obese Subjects With Insulin Resistance), which is not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Effect of a Lactobacillus Reuteri Strain on Markers of Inflammation, Cardiovascular Risk and Fatty Liver Disease in Obese Subjects With Insulin Resistance
Who cites it
34 citing papers in PubMed, 60 citations in OpenAlex.
- The promising effects of a multi-species synbiotic preparation on metabolic profile in elderly patients with type 2 diabetes and high cardiovascular risk: a randomized, triple-blind, placebo-controlled trial.Nutrition & diabetes · 2025Trial
- Trial
- Trial
- Effects and mechanisms of probiotics supplement on hypertension.Journal of hypertension · 2026Review
- Demystifying the role of postbiotics in inflammation mediated metabolic disorders: an updated review.Food science and biotechnology · 2026Review
- Multi-strain probiotics attenuate carbohydrate-lipid metabolic dysregulation in type 2 diabetic rats via gut-liver axis modulation.mSystems · 2025Article
- The Role of Probiotics in Modulating the Gut Microbiome in Alzheimer's Disease: A Review.Foods (Basel, Switzerland) · 2025Review
- Lactobacillus reuteri ZJ617 attenuates metabolic syndrome via microbiota-derived spermidine.Nature communications · 2025Article
- Higher estimated dietary intake of live microbes is associated with lower mortality in US adults.Frontiers in nutrition · 2025Article
- Application of probiotic therapy in nonalcoholic fatty liver disease: mediating mechanism and future perspective.Frontiers in cellular and infection microbiology · 2025Review
- Exploring Therapeutic Advances: A Comprehensive Review of Intestinal Microbiota Modulators.Antibiotics (Basel, Switzerland) · 2024Review
- Unlocking the gut-heart axis: exploring the role of gut microbiota in cardiovascular health and disease.Annals of medicine and surgery (2012) · 2024Review
- Gut microbiota and metabolite interface-mediated hepatic inflammation.Immunometabolism (Cobham, Surrey) · 2024Review
- Probiotics, prebiotics, synbiotics and other microbiome-based innovative therapeutics to mitigate obesity and enhance longevity via the gut-brain axis.Microbiome research reports · 2024Review
- Benefits of Biotics for Cardiovascular Diseases.International journal of molecular sciences · 2023Review
- Role of Gut Microbiome in Atherosclerosis: Molecular and Therapeutic Aspects.Current cardiology reviews · 2023Review
- The potential links between human gut microbiota and cardiovascular health and disease - is there a gut-cardiovascular axis?Frontiers in gastroenterology (Lausanne, Switzerland) · 2023Review
- Clinical Evidence on the Potential Beneficial Effects of Probiotics and Prebiotics in Cardiovascular Disease.International journal of molecular sciences · 2022Review
- Association of Dietary Live Microbe Intake with Cardiovascular Disease in US Adults: A Cross-Sectional Study of NHANES 2007-2018.Nutrients · 2022Article
- Intestinal microbiota in the treatment of metabolically associated fatty liver disease.World journal of clinical cases · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundObesity is characterized by increased fat mass and is associated with the development of insulin resistance syndrome (IRS), usually known as metabolic syndrome. The alteration of the intestinal microbiota composition has a role in the development of IRS associated with obesity, and probiotics, which are live microorganisms that confer a health benefit to the host, contribute to restore intestinal microbiota homeostasis and lower peripheral tissue insulin resistance. We aim to evaluate the effects of the probiotic strain Lactobacillus reuteri (L. reuteri) V3401 on the composition of intestinal microbiota, markers of insulin resistance and biomarkers of inflammation, cardiovascular risk, and hepatic steatosis in patients with overweight and obesity exhibiting IRS. METHODS/
designWe describe a randomized, double-blind, crossover, placebo-controlled, and single-centre trial. Sixty participants (aged 18 to 65 years) diagnosed with IRS will be randomized in a 1:1 ratio to receive either a daily dose of placebo or 5 × 10 DISCUSSION: This is the first time that L. reuteri V3401 will be evaluated in patients with IRS. Therefore, this study will provide valuable scientific information about the effects of this strain in metabolic syndrome patients.
trial registrationThe trial has been retrospectively registered in ClinicalTrials.gov on the 23rd November 2016 (ID: NCT02972567 ), during the recruitment phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.